DBV Technologies
IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children - Seite 3
DBV Technologies Contacts | |
Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 nathalie.donne@dbv-technologies.com |
Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 susanna.mesa@dbv-technologies.com |
DBV Technologies Media Contacts US & Europe | |
Marion Janic Rooney & Associates Tél. : +1-212-223-4017 mjanic@rooneyco.com |
Caroline Carmagnol Alize RP - Relation Presse Tél. : +33(0)6 64 18 99 59 caroline@alizerp.com |
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire
Lesen Sie auch
HUG#1935270
Aktuelle Themen
1 im Artikel enthaltener WertIm Artikel enthaltene Werte